Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 04280A100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Avoro Capital Advisors LLC
13G/A
Amendment 3
|
9.6% |
8/14/2026
Event 6/30/2026
|
|
| Avoro Capital Advisors LLC | 9.6% | ||
| Behzad Aghazadeh | 9.6% | ||
| Vanguard Portfolio Management LLC 13G/A Amendment 1 | 4.5% |
7/31/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G/A Amendment 6 | 10.1% |
7/27/2026
Event 6/30/2026
|
|
|
FMR LLC
13G
|
5.2% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 5.2% | ||
| Abigail P. Johnson | 5.2% | ||
| Vanguard Capital Management LLC 13G | 5.1% |
4/29/2026
Event 3/31/2026
|
|
| Vanguard Portfolio Management LLC 13G | 5.2% |
4/28/2026
Event 3/31/2026
|
|
| BlackRock, Inc. 13G/A Amendment 5 | 12.2% |
4/24/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 9 | 0% |
3/26/2026
Event 3/13/2026
|
|
| BlackRock, Inc. 13G/A Amendment 4 | 15.0% |
1/21/2026
Event 12/31/2025
|
|
|
Sarepta Therapeutics, Inc.
13D/A
Amendment 1
|
0% |
8/15/2025
Event 8/13/2025
|
|
| Sarepta Therapeutics, Inc. | 0% | ||
| Sarepta Therapeutics Investments, Inc. | 0% | ||
|
Avoro Capital Advisors LLC
13G/A
Amendment 2
|
8.3% |
8/14/2025
Event 6/30/2025
|
|
| Avoro Capital Advisors LLC | 8.3% | ||
| Behzad Aghazadeh | 8.3% | ||
| State Street Corp 13G | 4.6% |
8/11/2025
Event 6/30/2025
|
|
| Vanguard Group Inc 13G/A Amendment 8 | 11.2% |
7/29/2025
Event 6/30/2025
|
|
| State Street Corp 13G | 5.1% |
5/13/2025
Event 3/31/2025
|
|
| BlackRock, Inc. 13G/A Amendment 3 | 13.8% |
4/23/2025
Event 3/31/2025
|
|
|
Sarepta Therapeutics, Inc.
13D
|
9.5% |
2/14/2025
Event 2/7/2025
|
|
| Sarepta Therapeutics, Inc. | 9.5% | ||
| Sarepta Therapeutics Investments, Inc. | 9.5% | ||
|
Avoro Capital Advisors LLC
13G/A
Amendment 1
|
9.6% |
2/14/2025
Event 12/31/2024
|
|
| Avoro Capital Advisors LLC | 9.6% | ||
| Behzad Aghazadeh | 9.6% | ||
| State Street Corp 13G | 4.8% |
2/5/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 8 | 22.5 k | $1.45 M |
| 2026 Q2 | 529 | 131 M | $9.89 B |
| 2026 Q1 | 465 | 121 M | $7.58 B |
| 2025 Q4 | 428 | 116 M | $7.70 B |
| 2025 Q3 | 320 | 112 M | $3.85 B |
| 2025 Q2 | 304 | 106 M | $1.68 B |
| 2025 Q1 | 287 | 105 M | $1.34 B |
| 2024 Q4 | 290 | 99.7 M | $1.88 B |
| 2024 Q3 | 288 | 100 M | $1.94 B |
| 2024 Q2 | 293 | 102 M | $2.65 B |
| 2024 Q1 | 297 | 102 M | $2.90 B |
| 2023 Q4 | 291 | 82.2 M | $2.52 B |
| 2023 Q3 | 269 | 74.8 M | $2.01 B |
| 2023 Q2 | 294 | 72.4 M | $2.57 B |
| 2023 Q1 | 273 | 73.2 M | $1.86 B |
| 2022 Q4 | 303 | 79.5 M | $3.22 B |
| 2022 Q3 | 295 | 71.9 M | $2.37 B |
| 2022 Q2 | 295 | 72.4 M | $2.55 B |
| 2022 Q1 | 326 | 69.6 M | $3.20 B |
| 2021 Q4 | 338 | 68.4 M | $4.54 B |
| 2021 Q3 | 318 | 66.6 M | $4.16 B |
| 2021 Q2 | 336 | 67.3 M | $5.57 B |
| 2021 Q1 | 308 | 69.0 M | $4.58 B |
| 2020 Q4 | 345 | 70.1 M | $5.38 B |
| 2020 Q3 | 287 | 68.3 M | $2.95 B |
| 2020 Q2 | 279 | 69.0 M | $2.98 B |
| 2020 Q1 | 270 | 66.6 M | $1.93 B |
| 2019 Q4 | 325 | 66.6 M | $4.23 B |
| 2019 Q3 | 250 | 65.8 M | $1.86 B |
| 2019 Q2 | 237 | 68.6 M | $1.82 B |
| 2019 Q1 | 191 | 59.2 M | $1.09 B |
| 2018 Q4 | 175 | 59.6 M | $740 M |
| 2018 Q3 | 154 | 56.5 M | $1.08 B |
| 2018 Q2 | 129 | 51.9 M | $706 M |
| 2018 Q1 | 101 | 41.0 M | $296 M |
| 2017 Q4 | 87 | 23.4 M | $86.0 M |
| 2017 Q3 | 65 | 15.0 M | $64.9 M |
| 2017 Q2 | 67 | 15.4 M | $25.0 M |
| 2017 Q1 | 95 | 24.5 M | $45.4 M |
| 2016 Q4 | 100 | 25.9 M | $40.2 M |
| 2016 Q3 | 111 | 30.2 M | $222 M |
| 2016 Q2 | 97 | 20.6 M | $110 M |
| 2016 Q1 | 8 | 2.13 M | $10.3 M |
| 2015 Q4 | 1 | 500 | $4.00 k |
| 2015 Q3 | 1 | 500 | $3.00 k |
| 2015 Q2 | 1 | 500 | $4.00 k |
| 2015 Q1 | 1 | 500 | $4.00 k |
| 2014 Q4 | 1 | 500 | $4.00 k |